Concepedia

Michael Y. Choi

MY

60

Publications

3.9K

Citations

34

H-Index

2006

Active since

Affiliations

University of California San Diego(Current)

AbbVie (United States)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Cornell University

Michael Y. Choi is an author at University of California San Diego specializing in medicine, immunology, and oncology.

ORCID

Top concepts

Publications per year

2006–2024

60

Publications

60

Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells

Desheng Lu, Michael Y. Choi, Jian Yu et al. · Proceedings of the National Academy of Sciences · 2011 · 398 citations · Full text

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jeffrey A. Jones, Anthony R. Mato, William G. Wierda et al. · The Lancet Oncology · 2017 · 372 citations · Full text

, , +9

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

John F. Seymour, Shuo Ma, Danielle M. Brander et al. · The Lancet Oncology · 2017 · 321 citations · Full text

, , +10

Thrombospondins 1 and 2 are Necessary for Synaptic Plasticity and Functional Recovery after Stroke

Jason Liauw, Stanley Hoang, Michael Y. Choi et al. · Journal of Cerebral Blood Flow & Metabolism · 2008 · 266 citations · Full text

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

Michael Y. Choi, George F. Widhopf, Emanuela M. Ghia et al. · Cell stem cell · 2018 · 180 citations · Full text

, , +6

Rows per page

1–5 of 60